Dinaciclib in Treating Patients With Stage III-IV Melanoma

NCT01026324 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

NIH

Sponsor class

Stopped Slow accrual

Conditions

Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions

DRUG: dinaciclib
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)